Leveraging emerging evidence presented at AAN, Dr. Angela Hirbe provides synthesis of key findings, highlight their relevance across pediatric and adult care, and frame practical considerations for patient assessment and longitudinal management.

Launch/Release Date: April 24, 2026

Activity Expiration Date: March 31, 2027

FACULTY

Angela Hirbe, MD, PhD

Associate Professor of Medicine and Pediatrics

Director, Adult Neurofibromatosis Clinical Program

Division of Oncology, Sarcoma Section

Washington University School of Medicine

St. Louis, Missouri

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions.

In this 20-minute podcast episode, Dr. James Howard Jr. provides comprehensive coverage of key MG presentations, scientific symposia, posters, and abstracts presented at AAN 2026.

Launch/Release Date: April 23, 2026

Activity Expiration Date: March 31, 2027

FACULTY

James F. Howard, Jr., MD, FAAN

Professor of Neurology, Medicine & Allied Health

Director, Myasthenia Gravis Clinical Trials and Translational Research Program

The University of North Carolina at Chapel Hill

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.

Launch/Release Date: October 16, 2025

Activity Expiration Date: September 30, 2026

FACULTY

Angela Hirbe, MD, PhD

Associate Professor of Medicine and Pediatrics Director

Adult Neurofibromatosis Clinical Program Division of Oncology Sarcoma Section

Washington University School of Medicine

St. Louis, Missouri

This podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.